China has updated its pharmacopeia, its list of approved traditional and Western drugs, to remove traditional formulas with pangolin scales, offering hope for pangolin conservation - but also leaving some concerns about continued production. The new edition, effective Oct. 1, 2025, removes both raw pangolin scales and all formulas known to contain them, marking a significant step forward in conservation efforts, though conservationists caution that a few untracked formulas may still remain. The change reflects both international pressure, such as a 2022 resolution by the global wildlife trade convention, and growing internal advocacy within the traditional Chinese medicine (TCM) community for more sustainable practices. Despite the positive development, conservationists remain cautious, as changes to the pharmacopeia don’t amount to a full market ban, and China's domestic market for pangolin scales is still open under an annual 1-metric-ton quota, allowing continued production.